Navigation Links
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
Date:4/16/2009

the strength of the companies' current HIV products, as well as the complementary fit of Pfizer's HIV pipeline and GSK's global distribution capabilities, the new company is well positioned to bring new and improved medicines to patients with more speed and efficiency. The new company can reach more patients and accomplish much more for the treatment of HIV globally than either company on its own."

Focused new business with industry-leading HIV pipeline

The new company will have a broad product portfolio of 11 marketed products including market-leading therapies such as Combivir, Kivexa and Selzentry/Celsentri. Based on 2008 pro-forma results, this combined portfolio generated sales of approximately £1.6 billion and these revenues will provide the new company with financial stability and support investment in its pipeline.

The clear focus of the new business will be to invest in research and development of innovative HIV treatments and formulations that improve adherence and overcome resistance to the virus.

The company will have an industry-leading pipeline of 6 innovative and targeted medicines, including 4 compounds in phase II development. Altogether, the new company will have 17 molecules at its disposal to develop in fixed-dose combinations as possible new HIV treatments. The new company will contract R&D services directly from GSK and Pfizer to develop these medicines.

The new company will also invest in early-stage research and discovery of HIV medicines, and will benefit from a new Research Alliance Agreement with GSK and Pfizer. Under this new alliance, GSK and Pfizer will continue to conduct discovery research and development into HIV medicines and the new company will invest in this activity and will have exclusive rights of first negotiation in relation to any new HIV-related medicine developed by either GSK or Pfizer.


'/>"/>
SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
2. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
3. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
4. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
5. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
8. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
9. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
10. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
11. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LTC Consumer, an ... long term care insurance, features an Instant Quote tool on ... and co-founder of LTC Consumer. Quotes are free and unlimited. ... click in only seven areas – including age, gender, and ... screen within seconds (you don’t need to enter any contact ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
... Diabetes is the leading cause of end-stage kidney disease ... or a kidney transplant for survival. // ,A ... and the University of Heidelberg has proven that a ... kidney failure or "end-stage renal disease." ,The ...
... are facing one of the worst gastroenteritis epidemics that ... with patients coming// in droves for relief. The infection ... for a few days but seldom endangers life. ... Montreal area have reported the viral outbreak. Dr. Joseph ...
... have been created from blue green algae by scientists with ... on properties and actions of enzymes is also taken into ... possible to produce enough of the promising drugs for use ... the cover of the January issue of the journal ACS ...
... recent studies have shown that the chance of developing it ... the chances of surviving it, also depend on the same ... 50,000 pounds behind a study to be carried out by ... cancer survivors aged above fifty and with a BMI (Body ...
... detect infection of drug resistant forms of HIV even when ... the Duke University Medical Center. ,This new test ... in small amounts contrary to other tests that detect drug-resistant ... bloodstream. ,This new test is expected to be ...
Cached Medicine News:Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2Health News:Anti Cancer Drug from Blue Green Algae 2
(Date:7/30/2014)... SCHOFIELD, Wis. , July 30, 2014 /PRNewswire/ ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... is rebranding the LipiGesic ® M name along with ... will be replaced with the trademarked name MigraPure ... and color palette of PuraMed,s homeopathic, natural migraine ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 2Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 3Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 4Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 5Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 6Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 7Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 8Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 9Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 10Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 11Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 12Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 13Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 14Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 15Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 16Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 17Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 18Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 19Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 2Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 3Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 4Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 5Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 6
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... The Hall® Surgical E9000® System ... offers multiple electric handpieces specifically designed ... and Oral/Maxillofacial Surgery. The E9000 System ... console and 3 specialized handpieces designed ...
... USA™ Battery Tester is ... efficiently determine if your ... Extended Run, Stryker® 2115, ... Packs contain adequate charge ...
... offers a comprehensive line of high speed ... piece construction method that minimizes breakage. Using ... polished to create the sharpest edge possible, ... procedure., ,Our high speed cutters come ...
Medicine Products: